Hutchison China Meditech - WCLC: Positive Data Highlights Nsclc Pipeline
Edison | Dec 11, 2016 05:04AM ET
At the recent IASLC World Conference on Lung Cancer, Hutchison China MediTech Ltd (NASDAQ:HCM) published positive proof of concept data in NSCLC on key assets fruquintinib and epitinib. Affirmative data not only translates to further pipeline progression but critically underpins the R&D effort at HCM, fuelling the prospects of a fruquintinib regulatory filing in China in 2018. In 2017 we anticipate the initiation of three more pivotal trials, further data from the mid- to late-stage pipeline, including savolitinib data (papillary renal cell carcinoma, PRCC, and non-small cell lung cancer, NSCLC), and importantly potential China/US NDA submissions. We value HCM at $2.4bn or £32.2 share.
Spotlight on NSCLC: New data at IASLC WCLC
The recent proof of concept data published at IASLC WCLC in both the Phase II NSCLC trial with fruquintinib and the Phase Ib NSCLC trial with epitinib is highly encouraging. Importantly HCM has three TKIs in clinical development for NSCLC; each drug has a specific positioning and is truly differentiated: savolitinib (C-Met), fruquintinib (VEGFR) and epitinib (EGFR). Savolitinib has potential to be HCM’s first internationally launched asset (expect launch in US/EU/Japan in 2018). Depending on the strength of the NDA submission packages and speed of China FDA, we anticipate fruquintinib launch in China in 2018 and epitinib in 2019/20.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.